Cargando…
Future Directions in Cardiac Amyloidosis
Just a few years ago, cardiac amyloidosis (CA) was rarely diagnosed. With poor treatment options and delayed and infrequent diagnoses, most patients who were eventually recognized to have CA were referred for hospice care. Now, the availability of sponsored genetic testing, increased use of nuclear...
Autor principal: | Trachtenberg, Barry |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Houston Methodist DeBakey Heart & Vascular Center
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8932374/ https://www.ncbi.nlm.nih.gov/pubmed/35414857 http://dx.doi.org/10.14797/mdcvj.1071 |
Ejemplares similares
-
Status and Future Directions of Therapeutics and Prognosis of Cardiac Amyloidosis
por: Zhang, Wenbing, et al.
Publicado: (2023) -
A CHALLENGING DIAGNOSIS OF CARDIAC AMYLOIDOSIS IN THE COVID ERA
por: Satish, Priyanka, et al.
Publicado: (2021) -
Systemic AL amyloidosis: current approach and future direction
por: Bou Zerdan, Maroun, et al.
Publicado: (2023) -
Untangling Amyloidosis: Recent Advances in Cardiac Amyloidosis
por: Kim, Darae, et al.
Publicado: (2020) -
Cardiac Amyloidosis Treatment
por: Stern, Lily K., et al.
Publicado: (2022)